歌礼制药-B宣布其Asc30口服每日一次片剂在美国Ib期多次递增剂量研究中展现出良好且具有差异化的药代动力学特征
歌礼制药-B宣布其Asc30口服每日一次片剂在美国Ib期多次递增剂量研究中展现出良好且具有差异化的药代动力学特征
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.